Payment overview · 2025
General Payments
$909.67
35 reported records · 16 companies
Healthcare provider profile · identity verified
Rommel C Go, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOAZ, AL · NPI 1477548469
Verified facts
What the public records show
CMS Open Payments records show Rommel C Go, M.D. received $909.67 in general payments during 2025 across 35 reported records.
Xeris Pharmaceuticals, Inc. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Sublocade.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Sublocade by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $267.69 | 29.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.01 | 15.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.21 | 8.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.60 | 8.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.41 | 8.1% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $60.49 | 6.7% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $35.91 | 4.0% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $29.33 | 3.2% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $23.38 | 2.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.58 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.01 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.98 | 1.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.94 | 1.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.19 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.95 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.99 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $909.67 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $267.69 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $99.47 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.21 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $80.60 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.16 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $60.49 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.19 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 163 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
163 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 32 |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1959 | 317 |
| Gabapentin | Gabapentin | 1441 | 290 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 609 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 470 | 164 |
| Pregabalin | Pregabalin | 387 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 384 | 123 |
| Metformin Hcl | Metformin Hcl | 383 | 126 |
| Omeprazole | Omeprazole | 368 | 110 |
| Celecoxib | Celecoxib | 347 | 108 |
| Lisinopril | Lisinopril | 339 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 108 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 292 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 96 |
| Furosemide | Furosemide | 259 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 219 | 42 |
| Clonazepam | Clonazepam | 217 | 45 |
| Potassium Chloride | Potassium Chloride | 217 | 71 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 208 | 48 |
| Losartan Potassium | Losartan Potassium | 200 | 74 |
| Trazodone Hcl | Trazodone Hcl | 189 | 52 |
| Ozempic | Semaglutide | 187 | 45 |
| Montelukast Sodium | Montelukast Sodium | 186 | 59 |
| Tramadol Hcl | Tramadol Hcl | 180 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 175 | 57 |
| Carvedilol | Carvedilol | 166 | 52 |
| Farxiga | Dapagliflozin Propanediol | 163 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 53 |
| Meloxicam | Meloxicam | 155 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 150 | 44 |
| Simvastatin | Simvastatin | 148 | 53 |
| Mounjaro | Tirzepatide | 146 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 68 |
| Jardiance | Empagliflozin | 128 | 32 |
| Lidocaine | Lidocaine | 123 | 40 |
| Alendronate Sodium | Alendronate Sodium | 119 | 41 |
| Buspirone Hcl | Buspirone Hcl | 118 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 39 |
| Eliquis | Apixaban | 108 | 27 |
| Buprenorphine | Buprenorphine | 107 | 43 |
| Lorazepam | Lorazepam | 106 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 44 |
| Sertraline Hcl | Sertraline Hcl | 98 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 40 |
| Spironolactone | Spironolactone | 94 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 46 |
| Ibuprofen | Ibuprofen | 91 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 29 |
| Ezetimibe | Ezetimibe | 88 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 88 | 23 |
| Mirtazapine | Mirtazapine | 84 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 29 |
| Donepezil Hcl | Donepezil Hcl | 81 | 21 |
| Allopurinol | Allopurinol | 80 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 24 |
| Famotidine | Famotidine | 78 | 31 |
| Diazepam | Diazepam | 75 | 15 |
| Alprazolam | Alprazolam | 74 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 23 |
| Fenofibrate | Fenofibrate | 68 | 31 |
| Methocarbamol | Methocarbamol | 68 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 28 |
| Topiramate | Topiramate | 62 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 25 |
| Nystatin | Nystatin | 57 | 17 |
| Naproxen | Naproxen | 56 | 18 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 54 | 13 |
| Linzess | Linaclotide | 54 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 21 |
| Amoxicillin | Amoxicillin | 53 | 49 |
| Chlorthalidone | Chlorthalidone | 53 | 21 |
| Repatha Sureclick | Evolocumab | 50 | 12 |
| Valsartan | Valsartan | 49 | 18 |
| Estradiol | Estradiol | 47 | 13 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 47 | suppressed |
| Torsemide | Torsemide | 46 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 13 |
| Glimepiride | Glimepiride | 45 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Finasteride | Finasteride | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 42 | 15 |
| Promethazine Hcl | Promethazine Hcl | 42 | 18 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 16 |
| Rybelsus | Semaglutide | 41 | 13 |
| Trulicity | Dulaglutide | 41 | 13 |
| Azithromycin | Azithromycin | 40 | 38 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Fluocinonide | Fluocinonide | 37 | 22 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Glipizide | Glipizide | 36 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Risperidone | Risperidone | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 19 |
| Cephalexin | Cephalexin | 35 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 11 |
| Prednisone | Prednisone | 34 | 26 |
| Fluconazole | Fluconazole | 33 | 20 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Atenolol | Atenolol | 31 | 14 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Aripiprazole | Aripiprazole | 29 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Temazepam | Temazepam | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 11 |
| Etodolac | Etodolac | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 11 |
| Dutasteride | Dutasteride | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Colchicine | Colchicine | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 15 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sublocade | Buprenorphine | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $909.67 · 35 records | Xeris Pharmaceuticals, Inc. | AIRSUPRA, Auvelity, BREZTRI, BRIXADI, Cologuard Collection Kit, FANAPT, FARXIGA, JARDIANCE, JATENZO, JOURNAVX, Kerendia, Korlym, MAVYRET, RECORLEV, SUBLOCADE, The Cologuard Plus Collection Kit, VERQUVO, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error